By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Investigators publish new report on Biotechnology. According to news reporting originating in Quebec City, Canada, by NewsRx journalists, research stated, "Toll-like receptors (TLRs) have an important role in the activation of both innate and adaptive immunity in response to pathogens and danger signals. These receptors are expressed in immune cells and in some epithelia."
The news reporters obtained a quote from the research from Laval University, "They are expressed in the epithelium of the urinary bladder, where they actively participate in the fight against infection by uropathogens. TLR expression is decreased (although still evident) in bladder tumours, especially in non-muscle-invasive tumours. Intravesical immunotherapy with BCG to prevent recurrence of these tumours has been shown to involve the participation of three different TLRs (TLR2, TLR4, and TLR9). However, alternative therapies are needed as BCG fails in some patients and can sometimes cause severe adverse effects that are difficult to tolerate. In recent years, TLR2, TLR4, TLR7, and TLR9 agonists have been tested in vitro and in vivo for their ability to activate an antitumour immune response against bladder cancer."
According to the news reporters, the research concluded: "Promising results from these studies have led to the testing of TLR7 and TLR9 agonists in clinical trials."
For more information on this research see: Toll-like receptors in urothelial cells-targets for cancer immunotherapy. Nature Reviews Urology, 2013;10(9):537-545. Nature Reviews Urology can be contacted at: Nature Publishing Group, 75 Varick St, 9TH Flr, New York, NY 10013-1917, USA. (Nature Publishing Group - www.nature.com/; Nature Reviews Urology - www.nature.com/nrurol/)
Our news correspondents report that additional information may be obtained by contacting H. LaRue, Laval University, Center Rech Cancerol, CHU Quebec Hotel Dieu Quebec, Quebec City, PQ G1R 3S1, Canada. Additional authors for this research include C. Ayari, A. Bergeron and Y. Fradet (see also technology.html">Biotechnology).
Keywords for this news article include: Biotechnology, Canada, Cancer, Oncology, Immunology, Quebec City, Immunotherapy, Immunomodulation, Membrane Proteins, Toll-Like Receptors, North and Central America, Clinical Trials and Studies, Pattern Recognition Receptors
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC